ウェアラブル注射器市場（種類別、治療対象別、エンドユーザー別、地域別）：将来予測（2026～2032年）

ウェアラブル注射器市場の評価（2026～2032年）

ウェアラブル注射器はコンパクトで持ち運び可能なデザインであるため、患者は日常生活を続けながら簡単に薬を自己投与することができます。この利便性は、潜在的なヘルスケアコストの節約と相まって、今後数年間で需要を大幅に押し上げると予想されます。このように、利便性と携帯性が市場規模の成長を押し上げ、2024年には76億米ドルを突破し、2032年には214億8,000万米ドルの評価額に達します。

革新的な新薬を含むバイオ医薬品の進歩により、特殊なデリバリー・デバイスの必要性が高まっています。したがって、製薬業界の成長により、市場は2026年から2032年にかけて15.30%のCAGRで成長します。

ウェアラブル注射器市場の定義/概要

ウェアラブル注射器は、体内注射器やパッチポンプとしても知られ、特に生物学的薬剤や複雑な治療法を送達するための医療機器技術の顕著な進歩を表しています。これらのデバイスは、より大量の薬剤を長期間にわたって皮下投与するように設計されており、従来の静脈注射や毎日の頻繁な注射に代わる現代的な選択肢を提供します。皮膚に装着し、正確な投薬量を投与するようプログラムされたウェアラブル注射器は、患者の利便性と治療レジメンの遵守を大幅に向上させる。

主に糖尿病、関節リウマチ、多発性硬化症などの慢性疾患の管理に使用されるウェアラブル注射器は、頻繁な手動注射に比べて侵襲性が低く、より便利な選択肢を提供します。持続的あるいは定期的な投薬が可能で、治療の負担を軽減し、患者の快適性を向上させる。技術の進歩により、これらのデバイスはさらに使いやすくなり、ヘルスケアシステムに統合され、ドラッグデリバリーの改善、患者ケアの強化、医療成果の最適化が期待されます。

慢性疾患の有病率の上昇とマイクロ流体工学の革新は、ウェアラブル注射器市場の成長をどのように押し上げるか？

糖尿病、がん、心血管疾患などの慢性疾患の有病率の上昇により、ウェアラブル注射器の需要が大幅に増加しています。これらのデバイスは、定期的な投薬管理、治療コンプライアンスの向上、患者の転帰の改善に便利なソリューションを提供します。例えば、糖尿病患者は、持続的に皮下インスリンを投与するウェアラブルインスリンポンプの恩恵を受けており、毎日何度も注射するのに比べて血糖値を効果的に管理しています。マイクロ流体工学、無線通信、材料科学の技術進歩が、ウェアラブル注射器の人気をさらに押し上げています。マイクロ流体技術革新はドラッグデリバリーの正確な制御を可能にし、ワイヤレス接続はリアルタイムのモニタリングとデータ収集を可能にし、より良いアドヒアランスの追跡と治療調整を促進します。

在宅ヘルスケアへのシフトもウェアラブル注射器市場の主要な促進要因です。患者は、頻繁で費用のかかる通院を避けるために自宅での治療を好むが、ウェアラブル注射器は、専門家の補助を最小限に抑えて薬剤の自己投与を可能にすることで、このニーズに対応しています。COVID-19の流行時に加速したこの動向は、針刺し損傷などの問題にも対処し、医療従事者の関与の必要性を減らすことでヘルスケアコストを削減します。

さらに、バイオセンサー一体型ドラッグデリバリーシステムのような高度なデバイスの導入は、スマートポリマーとバイオMEMSを使用して継続的なモニタリングと正確な薬物放出を実現し、市場の成長をさらに促進します。これらの技術革新は、迅速で応答性の高い治療オプションを提供し、慢性疾患の管理を強化し、ウェアラブル注射器市場の拡大を支えています。

デバイス設計のユーザー体験と生体適合性・安全性の懸念は、ウェアラブル注射器市場の成長をどのように阻害するか？

ウェアラブル注射器の成功は、そのデザインとユーザー体験に大きく依存します。これらのデバイスは、患者のアドヒアランスと治療効果を確保するために、シンプルで快適、かつ信頼性の高いものでなければなりません。しかし、これらの基準を満たすデザインを実現するには大きな課題があります。ウェアラブル注射器は、患者の日常生活を妨げないように軽量で目立たないものである必要があり、同時に、特に手先が不自由な患者や認知障害のある患者にとって、自己投与が容易な直感的なユーザーインターフェースを備えている必要があります。ウェアラブル注射器は皮膚に直接触れ、体内に薬剤を投与するため、生体適合性と安全性が非常に重要です。

ウェアラブル注射器のコストが高いことが、普及の大きな障壁となっています。これらの機器は、その洗練された技術と、その製造に関わる広範な研究開発により、従来の注射法よりも高価です。製造コストが高いため、患者やヘルスケア・システム、特にコストを最も重視する中低所得国では、手が届かないこともあります。経口インスリンなどの代替ドラッグデリバリー法が利用可能であることも、ウェアラブル注射器市場にとっての課題です。

目次

第1章 世界のウェアラブル注射器市場：イントロダクション

• 市場概要
• 分析範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの分析手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界のウェアラブル注射器市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 世界のウェアラブル注射器市場：種類別

• 概要
• オンボディ注射器
• オフボディ注射器

第6章 世界のウェアラブル注射器市場：治療対象別

• 概要
• 免疫腫瘍
• 糖尿病
• 心血管疾患

第7章 世界のウェアラブル注射器市場：エンドユーザー別

• 概要
• 病院
• 診療所
• 在宅医療

第8章 世界のウェアラブル注射器市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋
• その他の地域 (ROW)
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界のウェアラブル注射器市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第10章 企業プロファイル

• Valeritas
• SteadyMed Therapeutics
• Tandem Diabetes Care
• Amgen
• Medtronic
• Insulet Corporation
• United Therapeutic Corporation
• Enable Injections
• Ypsomed
• Becton, Dickinson, and Company

第11章 主な動向

• 製品上市/開発
• 企業合併・買収 (M&A)
• 事業拡大
• 提携・協力

第12章 付録

• 関連分析

Wearable Injectors Market Valuation - 2026-2032

Wearable injectors' compact, portable design allows patients to self-administer medications easily while continuing daily activities. This convenience, combined with potential healthcare cost savings, is expected to boost demand significantly in the coming years. Thus, convenience and portability surge the growth of market size surpassing USD 7.6 Billion in 2024 to reach a valuation of USD 21.48 Billion by 2032.

Advancements in biopharmaceuticals, which involve new and innovative drugs, are increasing the need for specialized delivery devices. Thus, the growth in the pharmaceutical industry enables the market to grow at a CAGR of 15.30% from 2026 to 2032.

Wearable Injectors Market: Definition/ Overview

Wearable injectors, also known as on-body injectors or patch pumps, represent a notable advancement in medical device technology, particularly for delivering biological medications and complex therapies. These devices are engineered to administer larger doses of medication subcutaneously over extended periods, providing a modern alternative to traditional intravenous infusions and frequent daily injections. By being worn on the skin and programmed to deliver precise medication doses, wearable injectors significantly enhance patient convenience and adherence to treatment regimens.

Primarily used for managing chronic conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis, wearable injectors offer a less invasive and more convenient option compared to frequent manual injections. They allow for continuous or scheduled medication delivery, easing the burden of treatment and improving patient comfort. The advancements in technology are set to make these devices even more user-friendly and integrated into healthcare systems, promising improved drug delivery, enhanced patient care, and optimized healthcare outcomes.

How do the Rising Prevalence of Chronic Diseases and Innovations in Microfluidics Surge the Growth of the Wearable Injectors Market?

The rising prevalence of chronic conditions such as diabetes, cancer, and cardiovascular diseases has significantly increased the demand for wearable injectors. These devices offer a convenient solution for managing regular medication, enhancing treatment compliance, and improving patient outcomes. For instance, diabetic patients benefit from wearable insulin pumps that deliver continuous subcutaneous insulin, effectively managing blood glucose levels compared to multiple daily injections. Technological advancements in microfluidics, wireless communication, and materials science have further boosted the popularity of wearable injectors. Microfluidic innovations enable precise control over drug delivery rates, while wireless connectivity allows real-time monitoring and data collection, facilitating better adherence tracking and treatment adjustments.

The shift toward home-based healthcare is another major driver for the wearable injectors market. Patients prefer home treatments to avoid frequent, costly hospital visits, and wearable injectors accommodate this need by allowing the self-administration of medications with minimal professional assistance. This trend, which accelerated during the COVID-19 pandemic, also addresses issues like needle stick injuries and reduces healthcare costs by decreasing the need for healthcare worker involvement.

Additionally, the introduction of advanced devices like biosensor-integrated drug delivery systems, which use smart polymers and bioMEMS for continuous monitoring and precise drug release, further propels market growth. These innovations provide rapid, responsive treatment options, enhancing the management of chronic diseases and supporting the expansion of the wearable injectors market.

How do the Device Design User Experience and Biocompatibility and Safety Concerns Impede the Growth of the Wearable Injectors Market?

The success of wearable injectors largely depends on their design and user experience. These devices must be simple, comfortable, and reliable to ensure patient adherence and treatment effectiveness. However, achieving a design that meets these criteria poses significant challenges. Wearable injectors need to be lightweight and discreet to avoid disrupting patients' daily activities, while also featuring an intuitive user interface for easy self-administration, especially for patients with limited dexterity or cognitive impairments. Wearable injectors come into direct contact with the skin and deliver medication into the body, making biocompatibility and safety-critical.

The high cost of wearable injectors is a major barrier to their widespread adoption. These devices are more expensive than traditional injection methods due to their sophisticated technology and the extensive research and development involved in their creation. The high manufacturing costs can make them unaffordable for patients and healthcare systems, particularly in low- and middle-income countries, where cost considerations are paramount. The availability of alternative drug delivery methods, such as oral insulin, presents another challenge for the wearable injectors market.

Category-Wise Acumens

How does the Increasing Demand for Patient-Centric Treatment and the Growing Prevalence of Cancer Surge the Growth of the Immuno-Oncology Segment?

The immuno-oncology segment has emerged as the dominant force in the wearable injectors market due to the rising prevalence of various cancers, including breast, lung, bowel, and uterine cancers. This surge in cancer diagnoses has spurred demand for advanced, patient-centric treatment options. Immuno-oncology treatments, which use the body's immune system to combat cancer, often involve administering complex biological drugs like monoclonal antibodies and immune checkpoint inhibitors. These therapies require precise, continuous administration over extended periods, making wearable injectors a crucial tool.

The growing trend toward patient self-administration is further fueling the demand for wearable injectors. Traditional cancer treatments frequently require frequent healthcare visits for infusions, which can be costly and uncomfortable. Wearable injectors allow patients to administer their medications at home, enhancing convenience, improving quality of life, and reducing healthcare costs and facility strain. As the incidence of cancer increases, the need for scalable and accessible treatment solutions becomes more pressing. Wearable injectors address these needs by simplifying drug delivery and improving adherence to treatment plans, solidifying their importance in the immuno-oncology market and ensuring their continued growth.

How does the Increasing Demand for Devices and Automated Warming Surge the Growth of the On-Body Injectors Segment?

The on-body injectors segment has emerged as the largest revenue contributor in the wearable injectors market, driven by their numerous advantages and growing demand. Designed as patches worn comfortably on the skin, typically around the stomach area, on-body injectors have become highly preferred due to their user-friendly design, water-resistant properties, and suitability for home-based care. These devices are particularly valued for their convenience, as they deliver complex medications over extended periods, making them essential for managing chronic conditions. By allowing patients to self-administer medications at home, on-body injectors reduce the frequency of hospital visits, significantly lowering healthcare costs and alleviating the burden on medical facilities.

On-body injectors prioritize ease of use and patient comfort. Their lightweight, discreet design does not interfere with daily activities, leading to widespread adoption among various patient populations. The skin-friendly nature of these devices allows for extended wear without discomfort or irritation, further enhancing their appeal. The shift toward home-based care, accelerated by the COVID-19 pandemic, has driven the demand for on-body injectors, as patients increasingly prefer to receive treatments at home rather than frequent healthcare facilities.

How the Increasing Prevalence of Chronic Diseases and Advanced Healthcare Infrastructure Surge the Growth of Wearable Injectors Market in North America?

North America stands as the dominant region in the wearable injectors market, a position it is expected to maintain throughout the forecast period owing to its advanced healthcare infrastructure, high prevalence of chronic diseases, and early adoption of innovative technologies. The region's commitment to patient-centered care, alongside efforts to reduce healthcare costs and enhance treatment convenience, reinforces its leadership in this market. The rising incidence of chronic conditions, such as cancer and diabetes, has created a significant demand for efficient and reliable drug delivery systems. For instance, wearable insulin pumps have become crucial for managing diabetes by providing continuous subcutaneous insulin infusion and reducing the need for multiple daily injections.

The region has consistently led in medical device innovation, supported by substantial investments in research and development (R&D). This has facilitated the rapid advancement and adoption of sophisticated wearable injectors, which feature technologies like wireless connectivity, microfluidics, and patient monitoring systems. These innovations ensure more precise, efficient, and user-friendly drug delivery, which enhances patient outcomes and adherence to treatment regimens. Leading players in the region are actively engaged in product launches, mergers, acquisitions, and collaborations to expand their portfolios and market reach.

How does the Adoption of Wearable Medical Devices and Advanced Wearable Injectors Foster the Growth of the Wearable Injectors Market in Asia Pacific?

The Asia Pacific region is poised for the fastest growth in the wearable injectors market, driven by the widespread adoption of advanced medical technologies. Governments across the region, including those in China, India, and South Korea, are actively supporting this trend with favorable policies, subsidies, and streamlined regulatory processes that promote the use of wearable injectors. These initiatives aim to enhance healthcare infrastructure, address the needs of an aging population, and manage the rising incidence of chronic diseases.

The growing senior population, which faces higher risks of conditions such as diabetes, cardiovascular diseases, and cancer, further fuels the demand for wearable injectors. These devices offer a practical solution for self-administration, reducing the need for frequent hospital visits and improving patient management. As the geriatric demographic expands, the demand for wearable injectors is expected to accelerate significantly.

Competitive Landscape

The Wearable Injectors Market is a dynamic and competitive landscape. Key players are focused on innovation, partnerships, and market expansion to meet the growing demand for these devices. As the market continues to evolve, we can expect to see further advancements in wearable injector technology and increased adoption in various therapeutic areas.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the wearable injectors market include:

• Valeritas
• SteadyMed Therapeutics
• Tandem Diabetes Care
• Amgen
• Medtronic
• Insulet Corporation
• United Therapeutic Corporation
• Enable Injections
• Ypsomed
• Becton
• Dickinson and Company

Latest Developments:

• In February 2023, Insulet Corporation, a medical device business, announced the acquisition of Automated Glucose Control LLC's (AGC) assets. AGC was a key industry player in developing and commercializing automated insulin administration technologies.
• In May 2023, Enable Injections announced the collaboration with Viridian Therapeutics, Inc. to improve the patient experience using enFuse, a revolutionary wearable drug delivery device.
• In November 2022, Medtronic Plc announced the launch of the Medtronic Extended infusion set, a first-of-its-kind product that may be worn for up to 7 days in the United States. This infusion set is suitable for the MiniMed 600 and 700 series.
• In April 2021, Medtronic announced the launch of a wearable injector for diabetes therapy, which patients can wear for 7 days.

Wearable Injectors Market, By Category

• Type:
• On-Body Injectors
• Off-Body Injectors
• Hand Held
• Therapy:
• Immuno-Oncology
• Diabetes
• Cardiovascular Diseases
• Infectious Diseases
• End-User:
• Hospitals
• Home Care Settings
• Clinics
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL WEARABLE INJECTORS MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL WEARABLE INJECTORS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL WEARABLE INJECTORS MARKET, BY TYPE

• 5.1 Overview
• 5.2 On-Body Injectors
• 5.3 Off-Body Injectors

6 GLOBAL WEARABLE INJECTORS MARKET, BY THERAPY

• 6.1 Overview
• 6.2 Immuno-Oncology
• 6.3 Diabetes
• 6.4 Cardiovascular Diseases

7 GLOBAL WEARABLE INJECTORS MARKET, BY END-USER

• 7.1 Overview
• 7.2 Hospitals
• 7.3 Clinics
• 7.4 Home Care Settings

8 GLOBAL WEARABLE INJECTORS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL WEARABLE INJECTORS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Valeritas
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 SteadyMed Therapeutics
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Tandem Diabetes Care
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Amgen
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Medtronic
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Insulet Corporation
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 United Therapeutic Corporation
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Enable Injections
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Ypsomed
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Becton, Dickinson, and Company
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research